Disorders/differences of sexual development (DSD) are a group of conditions, some of which can be clinically indistinguishable mainly due to their phenotypic variability. Defining the molecular basis of their wide spectrum is still in progress. The diagnosis of 5-alpha-reductase type 2 (5α-reductase-2) deficiency is difficult especially in newborns and pre-pubertal individuals, and as a result its frequency might be underestimated. In the present study, we describe the clinical characteristics and molecular defects in 3 nonrelated 5α-reductase-2 deficiency patients of Bulgarian descent. Sequencing analysis revealed the mutations p.Y188CfsX9 and p.G196S, and MLPA analysis showed a deletion of exon 1 in the SRD5A2 gene. The observed genetic substitutions were not detected in 76 additionally screened unrelated controls, but a heterozygous healthy carrier of the p.R171S mutation was found. This is the first study on the molecular basis of 5α-reductase-2 deficiency in Bulgaria. It suggests that the carrier frequency of mutations in the SRD5A2 gene might be noteworthy worldwide. There is no correlation between cultural aspects, location, and/or population size and the number of different mutations in SRD5A2 detected, and more efforts should be made to determine the prevalence of this condition in different geographic areas. Our study supports the importance of genetic testing in 46,XY DSD patients, especially in countries or regions where 5α-reductase-2 deficiency has not been reported so far.

Keywords:
SRD5A2, Disorder of sexual development, Mutation analysis
1.
Akcay T, Fernandez-Cancio M, Turan S, Güran T, Audi L, Bereket A: AR and SRD5A2 gene mutations in a series of 51 Turkish 46,XY DSD children with a clinical diagnosis of androgen insensitivity. Andrology 2:572-578 (2014).
2.
Andersson S, Berman DM, Jenkins EP, Russell DW: Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 354:159-161 (1991).
3.
Baldinotti F, Majore S, Fogli A, Marrocco G, Ghirri P, et al: Molecular characterization of 6 unrelated Italian patients with 5alpha-reductase type 2 deficiency. J Androl 29:20-28 (2008).
4.
Berra M, Williams EL, Muroni B, Creighton SM, Honour JW, et al: Recognition of 5α-reductase-2 deficiency in an adult female 46,XY DSD clinic. Eur J Endocrinol 164:1019-1025 (2011).
5.
Bertelloni S, Baldinotti F, Russo G, Ghirri P, Dati E, et al: 5α-reductase-2 deficiency: clinical findings, endocrine pitfalls, and genetic features in a large Italian cohort. Sex Dev 10: 28-36 (2016).
6.
Boudon C, Lobaccaro JM, Lumbroso S, Ogur G, Ocal G, et al: A new deletion of the 5 alpha-reductase type 2 gene in a Turkish family with 5 alpha-reductase deficiency. Clin Endocrinol (Oxf) 43:183-188 (1995).
7.
Canto P, Vilchis F, Chavez B, Mutchinick O, Imperato-McGinley J, et al: Mutations of the 5α-reductase type 2 gene in eight Mexican patients from six different pedigrees with 5α-reductase 2 deficiency. Clin Endocrinol (Oxf) 46:155-160 (1997).
8.
Carpenter TO, Imperato-Mc Ginley J, Boulware SD, Weiss RM, Shackleton C, et al: Variable expression of 5α-reductase deficiency: presentation with male phenotype in a child of Greek origin. J Clin Endocrinol Metab 71:318-322 (1990).
9.
Chan AO, But BW, Lee CY, Lam YY, Ng KL, et al: Diagnosis of 5α-reductase 2 deficiency: is measurement of dihydrotestosterone essential? Clin Chem 59:798-806 (2013).
10.
Chávez B, Valdez E, Vilchis F: Uniparental disomy in steroid 5alpha-reductase 2 deficiency. J Clin Endocrinol Metab 85:3147-3150 (2000).
11.
Cheon CK: Practical approach to steroid 5 alpha-reductase type 2 deficiency. Eur J Pediatr 170:1-8 (2011).
12.
Cools M, Drop SL, Wolffenbuttel KP, Oosterhuis JW, Looijenga LH: Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers. Endocr Rev 27:468-484 (2006).
13.
Costa EM, Domenice S, Sircili MH, Inacio M, Mendonca BB: DSD due to 5α-reductase 2 deficiency - from diagnosis to long term outcome. Semin Reprod Med 30:427-431 (2012).
14.
Di Marco C, Bulotta AL, Varetti C, Dosa L, Michelucci A, et al: Ambiguous external genitalia due to defect of 5-α-reductase in seven Iraqi patients: prevalence of a novel mutation. Gene 526:490-493 (2013).
15.
Fénichel P, Paris F, Philibert P, Hiéronimus S, Gaspari L, et al: Molecular diagnosis of 5α-reductase deficiency in 4 elite young female athletes through hormonal screening for hyperandrogenism. J Clin Endocrinol Metab 98:E1055-E1059 (2013).
16.
Fernández-Cancio M, Audí L, Andaluz P, Torán N, Piró C, et al: SRD5A2 gene mutations and polymorphisms in Spanish 46,XY patients with a disorder of sex differentiation. Int J Androl 34:e526-e535 (2011).
17.
Forti G, Falchetti A, Santoro S, Davis DL, Wilson JD, Russell DW: Steroid 5 alpha-reductase 2 deficiency: virilization in early infancy may be due to partial function of mutant enzyme. Clin Endocrinol (Oxf) 44:477-482 (1996).
18.
Hackel C, Oliveira LE, Ferraz LF, Tonini MM, Silva DN, et al: New mutations, hotspots, and founder effects in Brazilian patients with steroid 5alpha-reductase deficiency type 2. J Mol Med 83:569-576 (2005).
19.
Imperato-McGinley J, Zhu YS: Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol 198:51-59 (2002).
20.
Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE: Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186:1213-1215 (1974).
21.
Imperato-McGinley J, Miller M, Wilson JD, Peterson RE, Shackleton C, Gajdusek DC: A cluster of male pseudohermaphrodites with 5 alpha-reductase deficiency in Papua New Guinea. Clin Endocrinol (Oxf) 34:293-298 (1991).
22.
Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, et al: Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients. J Clin Endocrinol Metab 96:296-307 (2011).
23.
Marzuki NS, Suciati LP, Dewi M, Tridjaja B: Two novel mutations of SRD5A2 gene in Indonesian siblings with clinical 5α-reductase deficiency. J Pediatr Endocrinol Metab 23:1329-1333 (2010).
24.
Mendonca BB, Inacio M, Costa EM, Arnhold IJ, Silva FA, et al: Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore) 75:64-76 (1996).
25.
Nagaraja MR, Rastogi A, Raman R, Gupta DK, Singh SK: Molecular diagnosis of 46,XY DSD and identification of a novel 8 nucleotide deletion in exon 1 of the SRD5A2 gene. J Pediatr Endocrinol Metab 23:379-385 (2010).
26.
Nicoletti A, Baldazzi L, Balsamo A, Barp L, Pirazzoli P, et al: SRD5A2 gene analysis in an Italian population of under-masculinized 46,XY subjects. Clin Endocrinol (Oxf) 63:375-380 (2005).
27.
Nie M, Zhou Q, Mao J, Lu S, Wu X: Five novel mutations of SRD5A2 found in eight Chinese patients with 46,XY disorders of sex development. Mol Hum Reprod 17:57-62 (2011).
28.
Nordenskjöld A, Ivarsson SA: Molecular characterization of 5 alpha-reductase type 2 deficiency and fertility in a Swedish family. J Clin Endocrinol Metab 83:3236-3238 (1998).
29.
Sahakitrungruang T, Wacharasindhu S, Yeetong P, Snabboon T, Suphapeetiporn K, Shotelersuk V: Identification of mutations in the SRD5A2 gene in Thai patients with male pseudohermaphroditism. Fertil Steril 90:2015.e11-15 (2008).
30.
Sasaki G, Ogata T, Ishii T, Kosaki K, Sato S, et al: Micropenis and the 5α-reductase 2 (SRD5A2) gene: mutation and V89L polymorphism analysis in 81Japanese patients. J Clin Endocrinol Metab 88:3431-3436 (2003).
31.
Sinnecker GH, Hiort O, Dibbelt L, Albers N, Dörr HG, et al: Phenotypic classification of male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency. Am J Med Genet 63:223-230 (1996).
32.
Skordis N, Neocleous V, Kyriakou A, Efstathiou E, Sertedaki A, et al: The IVS1-2A>G mutation in the SRD5A2 gene predominates in Cypriot patients with 5α reductase deficiency. J Endocrinol Invest 33:810-814 (2010).
33.
Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J, et al: Molecular genetics of steroid 5 alpha-reductase 2 deficiency. J Clin Invest 90:799-809 (1992).
34.
Veiga-Junior N, Medaets PA, Petroli RJ, Calais FL, de Mello MP, et al: Clinical and laboratorial features that nay differentiate 46,XY DSD due to partial androgen insensitivity and 5α-reductase type 2 deficiency. Int J Endocrinol 2012:964876 (2012).
35.
Vilchis F, Ramos L, Méndez JP, Benavides S, Canto P, Chávez B: Molecular analysis of the SRD5A2 in 46,XY subjects with incomplete virilization: the P212R substitution of the steroid 5alpha-reductase 2 may constitute an ancestral founder mutation in Mexican patients. J Androl 31:358-364 (2010).
36.
Walter KN, Kienzle FB, Frankenschmidt A, Hiort O, Wudy SA, et al: Difficulties in diagnosis and treatment of 5alpha-reductase type 2 deficiency in a newborn with 46,XY DSD. Horm Res Paediatr 74:67-71 (2010).
37.
Wigley WC, Prihoda JS, Mowszowicz I, Mendonca BB, New MI, et al: Natural mutagenesis study of the human steroid 5 alpha-reductase 2 isozyme. Biochemistry 33:1265-1270 (1994).
38.
Zhu H, Liu W, Han B, Fan M, Zhao S, et al: Phenotypic and molecular characteristics in eleven Chinese patients with 5α-reductase Type 2 deficiency. Clin Endocrinol (Oxf) 81:711-720 (2014).
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.